Pertuzumab was not added to protocol therapy based on prior data from NeoSphere suggesting limited incremental benefit of dual HER2 blockade on pCR rates in patients with ER+ and/or PR+/HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.